专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2014085154A1 METHODS FOR TREATING RENAL DISEASE 审中-公开
标题翻译：治疗肾病的方法
公开(公告)号：WO2014085154A1
公开(公告)日：2014-06-05
申请号：PCT/US2013/070908
申请日：2013-11-20
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： FRIEDMAN, David, J. , POLLAK, Martin, R.
IPC分类号： A61K38/00 , A61P13/12 , C12N15/11 , C07H21/04 , A61K39/395
CPC分类号： A61K31/519 , A61K31/429 , A61K31/4706 , A61K31/506 , A61K31/517 , A61K31/713 , A61K45/06 , C07D513/04 , C12N15/113 , C12N2310/14 , C12N2310/531
摘要： The invention features methods for treating or reducing the likelihood of developing a renal disease by administering to a subject in need thereof an agent that decreases expression of a pathogenic APOL1. The agents of the method target various signaling pathways and decrease the level of the pathogenic APOL1 polypeptide.
摘要翻译：本发明的特征在于通过向有需要的受试者施用降低致病性APOL1表达的试剂来治疗或降低发生肾脏疾病的可能性的方法。该方法的药物靶向各种信号通路并降低致病性APOL1多肽的水平。

52. 发明申请

WO2013112458A1 NOVEL CHREBP ISOFORMS AND METHODS USING THE SAME 审中-公开
标题翻译：使用它的新型CHREBP ISOFORMS和方法
公开(公告)号：WO2013112458A1
公开(公告)日：2013-08-01
申请号：PCT/US2013/022521
申请日：2013-01-22
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
发明人： HERMAN, Mark, A. , KAHN, Barbara, B.
IPC分类号： C12Q1/68
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/502 , G01N2333/47 , G01N2500/04 , G01N2500/10 , G01N2800/042 , G01N2800/52 , G01N2800/56
摘要： The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by detecting the levels of a novel isoform of ChREBP, termed ChREBP β. The invention also provides nucleic acids, proteins, reporter constructs based on ChREBP β and methods of identifying one or more agents that modulate the expression of a ChREBP β target gene.
摘要翻译：本发明提供了通过检测称为ChREBPβ的ChREBP的新型同工型的水平来评估诸如肥胖症，糖尿病，代谢综合征，癌症和血管疾病的疾病的治疗方案的诊断和预后方法和方法。本发明还提供了基于ChREBPβ的核酸，蛋白质，报告基因构建体以及鉴定调节ChREBPβ靶基因表达的一种或多种试剂的方法。

53. 发明申请

WO2013016279A1 ANIMAL MODEL OF AUTISM 审中-公开
标题翻译：动物模型
公开(公告)号：WO2013016279A1
公开(公告)日：2013-01-31
申请号：PCT/US2012/047839
申请日：2012-07-23
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , ANDERSON, Matthew, P.
发明人： ANDERSON, Matthew, P.
IPC分类号： C12N5/10 , C12N15/85 , C12N15/52 , A01K67/027 , G01N33/15
CPC分类号： A01K67/0278 , A01K2217/052 , A01K2227/105 , A01K2267/0356 , C12N9/93 , C12N15/8509 , C12N2015/8536 , C12N2517/02 , C12Q1/25 , G01N33/573
摘要： Some aspects of this invention provide a non-human animal model of autism. Some aspects of this invention provide a non-human animal model for diseases or disorders associated with an overexpression or a copy number variance of a Ube3a gene. Transgenic mammals and transgenic mammalian cells comprising an exogenous copy or exogenous copies of a ube3a protein-encoding nucleic acid sequence are also provided. Some aspects of this invention further provide methods for using the animal models, cells, and transgenic animals for identifying agents or interventions that can alleviate a pathogenic characteristic observed in the animal model, cell, or transgenic animal.
摘要翻译：本发明的一些方面提供了一种非人类自闭症动物模型。本发明的一些方面提供了与Ube3a基因的过度表达或拷贝数变异相关的疾病或病症的非人动物模型。还提供了转基因哺乳动物和包含外源拷贝或编码ube3a蛋白的核酸序列的外源拷贝的转基因哺乳动物细胞。本发明的一些方面进一步提供了使用动物模型，细胞和转基因动物来鉴定可以减轻在动物模型，细胞或转基因动物中观察到的致病特征的试剂或干预的方法。

54. 发明申请

WO2012162394A3 COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASE 审中-公开
公开(公告)号：WO2012162394A3
公开(公告)日：2012-11-29
申请号：PCT/US2012/039145
申请日：2012-05-23
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , FRIEDMAN, David, J. , POLLAK, Martin, R.
发明人： FRIEDMAN, David, J. , POLLAK, Martin, R.
IPC分类号： A61K38/00 , A61K31/7088 , C12N15/113
摘要： Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOLl and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOLl, nucleic acid molecules that encode the common variant of APOLl and fragments thereof, and other compounds that bind and neutralize pathogenic APOLl. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease.

55. 发明申请

WO2012119091A1 MCL-1 AS A THERAPEUTIC TARGET IN SCFFBW7 DEFICIENT NEOPLASM 审中-公开
标题翻译： MCL-1作为SCFFBW7中的治疗目标缺乏的NEOPLASM
公开(公告)号：WO2012119091A1
公开(公告)日：2012-09-07
申请号：PCT/US2012/027516
申请日：2012-03-02
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , WEI, Wenyi
发明人： WEI, Wenyi
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , A61K31/44 , A61K31/495 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/574
摘要： Some embodiments are based on the discovery that proliferative diseases (e.g., neoplastic diseases, for example, tumors or cancers) having an FBW7 mutation or other FBW7 deficiency are sensitive to Mcll inhibiting agents, but resistant to pro-apoptotic drugs that do not inhibit Mcll. Some embodiments provide methods of treating a proliferative disease based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of classifying a hyperproliferative cell or cell population, for example, a malignant cell or cell population based on an assessment of FBW7 expression level or mutation status. Some embodiments provide methods of selecting a treatment regimen for treating a proliferative disease, for example, a malignant disorder, based on an assessment of FBW7 expression level or mutation status.
摘要翻译：一些实施方案基于以下发现：具有FBW7突变或其他FBW7缺陷的增殖性疾病（例如肿瘤或癌症）对Mcll抑制剂敏感，但对不抑制Mcll的促凋亡药物具有抗性。一些实施方案提供了基于FBW7表达水平或突变状态的评估来治疗增殖性疾病的方法。一些实施方案提供了基于FBW7表达水平或突变状态的评估来分类过度增殖细胞或细胞群体，例如恶性细胞或细胞群体的方法。一些实施方案提供了基于FBW7表达水平或突变状态的评估来选择用于治疗增殖性疾病，例如恶性疾病的治疗方案的方法。

56. 发明申请

WO2012061268A1 COMPOSITIONS AND METHODS FOR TREATING ANTIPHOSPHOLIPID SYNDROME 审中-公开
标题翻译：用于治疗抗磷脂综合征的组合物和方法
公开(公告)号：WO2012061268A1
公开(公告)日：2012-05-10
申请号：PCT/US2011/058522
申请日：2011-10-31
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , BEGLOVA, Natalia
发明人： BEGLOVA, Natalia
IPC分类号： A61K38/00
CPC分类号： C07K14/705 , A61K38/00 , A61K38/177 , C07K14/775 , C07K2319/21 , C07K2319/50
摘要： The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target β20ΡΙ in p2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker.
摘要翻译：本发明的特征在于使用二聚体抑制剂例如A1-A1的组合物和方法选择性地靶向ß20？在p2GPI /抗体复合物中。为了治疗或抑制疾病或治疗或减轻其症状，组合物可以施用于具有或可能发展APS的受试者（例如哺乳动物，例如人）或APS的一种或多种症状。本发明的抑制剂包括两个配体结合的A1模块，例如来自ApoER2，通过柔性接头连接。

57. 发明申请

WO2011008641A1 METHIDS OF MODULATING ANGIOGENESIS AND TREATMENT OF ANGIOGENESIS-RELATED DISEASES 审中-公开
标题翻译：调节血管发生和治疗血管发生相关疾病的甲状腺
公开(公告)号：WO2011008641A1
公开(公告)日：2011-01-20
申请号：PCT/US2010/041484
申请日：2010-07-09
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , AN, Xiaojin , LI, Jian
发明人： AN, Xiaojin , LI, Jian
IPC分类号： C07K14/47 , C12N15/113
CPC分类号： C07K14/4702 , C07K14/82 , C12N15/113 , C12N15/1135 , C12N2310/11 , C12N2310/14 , C12N2310/3181 , C12N2310/3233
摘要： The present invention relates to a novel function for RGC-32 as an inhibitor of angiogenesis and a mediator between VEGF and FGF2 pathways. The present invention provides that expression of RGC-32 is induced in endothelial cells under hypoxia and that overexpression of RGC-32 in endothelial cells inhibited endothelial cell proliferation and migration via downregulation of another major angiogenic protein, FGF2, to further effect cyclin E. Also, RGC-32 promoted unstable vascular structure by increasing the numbers of apoptotic cells. The present invention provides methods of inhibiting proliferation of endothelial cells, angiogenesis, tumor growth by increasing expression of RGC-32 in the endothelial cells. The present invention relates to methods of increasing proliferation of endothelial cells as well as methods of treating ischemia by inhibiting expression of RGC-32 in the endothelial cells.
摘要翻译：本发明涉及RGC-32作为血管生成抑制剂和VEGF与FGF2途径之间介导的新功能。本发明提供了在缺氧下内皮细胞中诱导RGC-32的表达，并且内皮细胞中RGC-32的过度表达通过下调另一种主要血管生成蛋白FGF2来抑制内皮细胞增殖和迁移，从而进一步影响细胞周期蛋白E. RGC-32通过增加凋亡细胞的数量来促进血管结构的不稳定。本发明提供通过增加内皮细胞中RGC-32的表达来抑制内皮细胞增殖，血管发生，肿瘤生长的方法。本发明涉及通过抑制内皮细胞中RGC-32的表达来增加内皮细胞增殖的方法以及治疗缺血的方法。

58. 发明申请

WO2010042942A3 BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE 审中-公开
公开(公告)号：WO2010042942A3
公开(公告)日：2010-04-15
申请号：PCT/US2009/060494
申请日：2009-10-13
申请人： CHILDREN'S MEDICAL CENTER CORPORATION , BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , HARRISON, Stephen, C. , CHEN, Bing , BAROUCH, Dan, H. , NKOLOLA, Joseph, P. , SEAMAN, Michael, Scott
发明人： HARRISON, Stephen, C. , CHEN, Bing , BAROUCH, Dan, H. , NKOLOLA, Joseph, P. , SEAMAN, Michael, Scott
IPC分类号： A61K38/00
摘要： Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

59. 发明申请

WO2009126289A2 POSITIVE MAGNETIC RESONANCE IMAGING CONTRAST METHODS AND APPARATUS USING CHEMICAL EXCHANGE SATURATION TRANSFER 审中-公开
标题翻译：利用化学交换饱和转移的正磁共振成像对比方法和装置
公开(公告)号：WO2009126289A2
公开(公告)日：2009-10-15
申请号：PCT/US2009/002221
申请日：2009-04-09
申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , VINOGRADOV, Elena , LENKINSKI, Robert, E.
发明人： VINOGRADOV, Elena , LENKINSKI, Robert, E.
IPC分类号： A61B5/055
CPC分类号： G01R33/485 , G01N24/087 , G01R33/5601
摘要： In one aspect, an apparatus for performing chemical exchange saturation transfer (CEST) magnetic resonance imaging on a region of an object being imaged is provided. The method comprises at least one coil capable of being operated to emit radio frequency (RF) signals, at least one detector capable of detecting nuclear magnetic resonance signals, and at least one controller to operate the at least one coil to provide at least one inversion sequence to the region to flip at least some spins in the region by a desired flip-angle, operate the at least one coil to provide at least one first pulse sequence at a first frequency offset from a peak resonant frequency of water by a first amount in a first direction to magnetize at least one exchange group in the region, operate the at least one coil to provide at least one second pulse sequence at a second frequency offset from the peak resonant frequency of water by the first amount in a second direction opposite the first direction, operate the at least one detector to measure a first signal emitted from the region as a result of providing the at least one first pulse sequence after a predetermined time interval after applying the first inversion sequence, and operate the at least one detector to measure a second signal emitted from the region as a result of providing the at least one second sequence at the predetermined time interval after applying the at least one inversion sequence, wherein the predetermined time interval is selected such that positive contrast is achieved with respect to the first signal relative to the second signal.
摘要翻译：在一个方面，提供了一种用于在正被成像的物体的区域上执行化学交换饱和转移（CEST）磁共振成像的装置。该方法包括至少一个能够被操作以发射射频（RF）信号的线圈，至少一个能够检测核磁共振信号的检测器以及至少一个控制器以操作至少一个线圈以提供至少一个反转序列到该区域以翻转该区域中的至少一些自旋达期望的翻转角，操作该至少一个线圈以提供至少一个第一脉冲序列，该第一脉冲序列在距水的峰值谐振频率第一频率偏移第一量在使所述区域中的至少一个交换组磁化的第一方向上，操作所述至少一个线圈以提供至少一个第二脉冲序列，所述第二脉冲序列在相对于水的峰值谐振频率的第二频率偏移第一量的第二方向作为在预定时间之后提供所述至少一个第一脉冲序列的结果，所述第一方向操作所述至少一个检测器以测量从所述区域发射的第一信号在施加所述至少一个反转序列之后，作为在所述预定时间间隔提供所述至少一个第二序列的结果，操作所述至少一个检测器以测量从所述区域发射的第二信号，其中，预定时间间隔被选择为使得相对于第一信号相对于第二信号实现正对比度。

60. 发明申请

WO2009020528A1 VACUOLAR PYROPHOSPHATASES AND USES IN PLANTS 审中-公开
标题翻译： VACUOLAR PYROPHOSPHATASES和在植物中的用途
公开(公告)号：WO2009020528A1
公开(公告)日：2009-02-12
申请号：PCT/US2008/009091
申请日：2008-07-28
申请人： UNIVERSITY OF CONNECTICUT , WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH , BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , GAXIOLA, Roberto, A. , FINK, Gerald, R. , ALPER, Seth, L.
发明人： GAXIOLA, Roberto, A. , FINK, Gerald, R. , ALPER, Seth, L.
IPC分类号： C12N15/82
CPC分类号： C12N15/8259 , C12N15/8261 , C12N15/8273 , Y02A40/146
摘要： The present invention relates to a transgenic plant which is tolerant to a salt, comprising one or more plant cells transformed with exogenous nucleic acid which alters expression of vacuolar pyrophosphatase in the plant. The present invention also relates to a transgenic plant with increased Pi uptake, comprising one or more plant cells transformed with exogenous nucleic acid which alters expression of vacuolar pyrophosphatase in the plant. Also encompassed by the present invention are transgenic progeny and seeds of the transgenic plants described herein. Progeny transgenic plant grown from seed are also described. Plant cells (e.g., root cells, stem cell, leaf cells, flower cells, fruit cells and seed cells) comprising exogenous nucleic acid which alters expression of vacuolar pyrophosphatase in the plant cell are also the subject of the present invention. Also encompassed by the present invention are methods of making a transgenic plant described herein. Transgenic plants produced by the methods of making a transgenic plant as described herein are also a subject of the present invention. The present invention also relates to a method of bioremediating soil, a method of increasing the yield of a plant, a method of making a plant which is larger than its corresponding wild type plant, a method of producing a transgenic plant which grows in salt water, and a method of producing a transgenic plant with increased Pi uptake. The transgenic plants of the present invention can also be used to produce double transgenic plants which are tolerant to a salt, or have increased Pi uptake.
摘要翻译：本发明涉及对盐具有耐受性的转基因植物，其包含用外源核酸转化的一种或多种植物细胞，其改变植物中液泡焦磷酸酶的表达。本发明还涉及具有增加的Pi摄取的转基因植物，其包含用外源核酸转化的一种或多种植物细胞，其改变植物中液泡焦磷酸酶的表达。本发明还包括本文所述的转基因植物的转基因后代和种子。还描述了从种子生长的后代转基因植物。包含改变植物细胞中液泡焦磷酸酶表达的外源核酸的植物细胞（例如根细胞，干细胞，叶细胞，花细胞，果实细胞和种子细胞）也是本发明的主题。本发明还包括制备本文所述的转基因植物的方法。通过制备如本文所述的转基因植物的方法产生的转基因植物也是本发明的主题。本发明还涉及一种生物中和土壤的方法，提高植物产量的方法，制备大于其相应野生型植物的植物的方法，生产在盐水中生长的转基因植物的方法，以及生产具有增加的Pi摄取的转基因植物的方法。本发明的转基因植物也可以用于产生耐受盐或具有增加的Pi吸收的双转基因植物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式